Stock listing

NASDAQ:NRXP NRX Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of NRX Pharmaceuticals, Inc.

Follow NRX Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:NRXP

$2.15 USD -0.40 (-15.7%)

Close on Nov 20, 2026

Past year +5.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.14 – $2.53 USDNov 20, 2026
Volume
1.48M sharesNov 20, 2026
Market cap
$95.31M USDAt the close on Nov 20, 2026 · price × 44.33M shares outstanding
52-week range
$1.62 – $5.06 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.87M USDMedian day 722,101 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
NRX Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:NRXP · Home$2.15 USD-0.40 (-15.7%)1,475,335$2.53$2.53$2.135$2.55Close on Nov 20, 2026
Frankfurt:B1Q€2.27 EUR-0.375 (-14.2%)1,000€2.23€2.27€2.23€2.645Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NRXP · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.15-0.40-15.7%$2.53$2.53$2.1351,475,335
$2.55-0.25-8.9%$2.86$2.885$2.521,397,394
$2.80+0.35+14.3%$2.46$2.91$2.462,162,095
$2.45+0.30+14.0%$2.145$2.47$2.091,598,434
$2.15-0.04-1.8%$2.16$2.195$2.052728,159
$2.19-0.09-3.9%$2.25$2.26$2.1651,030,551
$2.28-0.16-6.6%$2.43$2.44$2.25605,046
$2.44+0.08+3.4%$2.39$2.50$2.36980,128
$2.36-0.02-0.8%$2.32$2.40$2.29497,771
$2.380.000.0%$2.38$2.44$2.26878,548
$2.38+0.11+4.8%$2.30$2.40$2.26604,422
$2.27-0.22-8.8%$2.46$2.48$2.241832,743
$2.49+0.25+11.2%$2.30$2.51$2.301,130,890
$2.24+0.07+3.2%$2.165$2.34$2.111,799,900
$2.17-0.10-4.4%$2.32$2.44$2.142,510,312
$2.27-0.39-14.7%$2.83$2.84$2.1115,641,670
$2.66-0.03-1.1%$2.70$2.773$2.6151,760,886
$2.690.000.0%$2.73$2.745$2.64834,661
$2.69+0.14+5.5%$2.59$2.705$2.53749,684
$2.55+0.06+2.4%$2.48$2.59$2.459594,734
$2.49+0.09+3.8%$2.36$2.50$2.24840,297
$2.40-0.23-8.7%$2.57$2.61$2.361,051,688
$2.63+0.01+0.4%$2.65$2.70$2.61526,552
$2.62-0.01-0.4%$2.63$2.77$2.5451,348,553
$2.63+0.03+1.2%$2.815$2.815$2.6231,093,428
$2.60-0.11-4.1%$2.70$2.76$2.5721,226,911
$2.71+0.12+4.6%$2.53$2.772$2.481,177,679
$2.59-0.11-4.1%$2.64$2.705$2.56696,336
$2.70-0.15-5.3%$2.85$2.85$2.675553,869
$2.850.000.0%$2.85$2.93$2.815481,039
$2.85-0.04-1.4%$2.89$2.89$2.82289,405
$2.89-0.01-0.3%$2.88$2.895$2.805651,765
$2.90-0.04-1.4%$2.88$2.93$2.87405,069
$2.94+0.07+2.4%$2.89$2.975$2.825418,910
$2.87-0.035-1.2%$2.91$2.93$2.785680,823
$2.905+0.055+1.9%$2.91$2.94$2.82613,067
$2.85-0.07-2.4%$2.94$3.00$2.833625,975
$2.920.000.0%$3.035$3.06$2.911,172,268
$2.92+0.05+1.7%$2.92$2.97$2.87515,784
$2.87-0.125-4.2%$2.95$3.01$2.87736,822
$2.995-0.035-1.2%$3.07$3.09$2.92793,377
$3.03-0.13-4.1%$3.15$3.15$3.025681,052
$3.16-0.16-4.8%$3.29$3.35$3.12552,500
$3.32+0.03+0.9%$3.30$3.33$3.21495,041
$3.29-0.03-0.9%$3.37$3.39$3.29380,010
$3.32-0.07-2.1%$3.38$3.42$3.31947,272
$3.39+0.04+1.2%$3.38$3.52$3.36789,018
$3.35-0.05-1.5%$3.39$3.45$3.32716,043
$3.40-0.09-2.6%$3.46$3.47$3.161,257,746
$3.49+0.09+2.6%$3.37$3.605$3.351,205,425
$3.400.000.0%$3.44$3.44$3.37356,231
$3.40+0.03+0.9%$3.36$3.45$3.32480,116
$3.37-0.10-2.9%$3.48$3.52$3.34520,713
$3.47-0.02-0.6%$3.50$3.54$3.42705,974
$3.49+0.06+1.7%$3.43$3.50$3.39487,720
$3.43-0.03-0.9%$3.48$3.50$3.425237,362
$3.46+0.02+0.6%$3.46$3.50$3.38418,341
$3.44-0.04-1.1%$3.45$3.51$3.42392,760
$3.48-0.07-2.0%$3.52$3.545$3.43427,013
$3.55-0.07-1.9%$3.63$3.68$3.50695,596
$3.62+0.16+4.6%$3.51$3.62$3.47584,036
$3.46-0.21-5.7%$3.62$3.62$3.381,011,362
$3.67+0.22+6.4%$3.49$3.69$3.425895,953
$3.45-0.11-3.1%$3.52$3.61$3.44898,336
$3.56+0.05+1.4%$3.52$3.60$3.44615,302
$3.51+0.18+5.4%$3.36$3.55$3.33811,738

Splits

1 split · NASDAQ:NRXP · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
Ticker
NASDAQ:NRXP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All NRX Pharmaceuticals, Inc. news

NRX Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
51 in the last 12 months · 276 in all · newest Nov 17, 2026 · oldest 2021
Calls
22 calls with a replay · 22 with a transcript · latest Nov 17, 2026
Decks
10 decks · latest Sep 14, 2026

Where NRX Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:NRXP · Home listing · This pageNASDAQUnited StatesUSD
LS Exchange:A4091KLS ExchangeGermanyEUR
Lang & Schwarz:A4091KLang & SchwarzGermanyEUR
BOATS:NRXPBOATSUnited StatesUSD
gettex:B1QgettexGermanyEUR
Tradegate:B1QTradegateGermanyEUR
Frankfurt:B1QFrankfurtGermanyEUR
Hamburg:B1QHamburgGermanyEUR
Munich:B1QMunichGermanyEUR

Valuation

EV/sales 17.7× against a median of 1.6×: the highest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$76.46M USD
P/E
Loss
EV/sales
17.7×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
29.9%
Operating margin
−557.1%
Net margin
−458.5%
Debt to equity
Negative equity
Beta vs S&P 500
2.23

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
NRX Pharmaceuticals, Inc. · NASDAQ:NRXPUS$95.31MUS$76.46Mn/a17.7×n/an/a−458.5%n/a2.23
Unicycive Therapeutics, Inc. · NASDAQ:UNCYUS$97.77MUS$39.32Mn/an/an/a1.9×n/a0.0×1.09
NovaBridge Biosciences · NASDAQ:NBPUS$96.28MUS$68.30Mn/an/an/a3.2×n/a0.0×1.37
Wuhan YZY Biopharma Co., Ltd. Class H · HKEX:2496US$96.17MUS$105.6Mn/a7.8×n/an/a−53.2%n/an/a
PDS Biotechnology Corporation · NASDAQ:PDSBUS$95.39MUS$80.15Mn/an/an/a7.1×n/a0.0×2.04
Immunic, Inc. · NASDAQ:IMUXUS$95.37M−US$36.09Mn/an/an/a0.9×n/a0.0×1.51
Allergy Therapeutics plc · LSE:AGYUS$95.27MUS$117.1Mn/a1.6×n/a17.1×−72.9%6.3×n/a
Voyager Therapeutics, Inc. · NASDAQ:VYGRUS$95.21M−US$11.60Mn/a−0.5×n/a0.7×−416.3%0.0×1.45
Outlook Therapeutics, Inc. · NASDAQ:OTLKUS$94.94MUS$83.70Mn/an/an/an/an/an/a1.10
Molecular Partners AG · SIX:MOLNUS$93.53M−US$4.92Mn/an/an/a1.0×n/a0.0×n/a
Sunhawk Vision Biotech, Inc. · TPEX:7759US$93.04MUS$82.43Mn/an/an/a7.3×n/a0.0×n/a
Median of the othersUS$95.32MUS$74.22M1.6×2.5×−72.9%0.0×1.41

Forecasts

3 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
39.25 USD · Analysts' mean
EPS, year to Dec 2026
-0.80 · 1 analyst
Revenue, year to Dec 2026
5.61M · 4 analysts

Team and board

Officers

OfficerRole
Jonathan C. JavittFounder, Chairman & Chief Scientist; Co-CEO HOPE Therapeutics
Michael AbramsChief Financial Officer
Patrick FlynnChief Operating Officer
Dennis K. McBrideChief Strategy Officer
Glenn D. TysonChief Commercial Officer
Hope TherapeuticsInc.Chief Business Officer
Joshua BrownChief Medical Innovation Officer
Rick PanicucciChief Technology Officer

Board

DirectorRole
Jonathan C. JavittFounder, Chairman & Chief Scientist; Co-CEO HOPE Therapeutics
Brian KorbManaging Partner, astr partners
Chaim HurvitzDirector
Dennis K. McBrideChief Strategy Officer
Patrick FlynnChief Operating Officer

Events

Calls

CallWhenStatus
NRX Pharmaceuticals (NASDAQ:NRXP) Q3 2026 Earnings CallTue, Nov 17, 2026 · 8:00 AM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q2 2026 Earnings CallMon, Aug 17, 2026 · 4:30 PM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q1 2026 Earnings CallMon, May 18, 2026 · 8:00 AM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q4 2025 Earnings CallTue, Mar 24, 2026 · 8:00 AM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q3 2025 Earnings CallMon, Nov 17, 2025 · 8:30 AM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q2 2025 Earnings CallWed, Aug 20, 2025 · 8:00 AM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q1 2025 Earnings CallThu, May 15, 2025 · 4:30 PM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q4 2024 Earnings CallMon, Mar 17, 2025 · 8:30 AM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q3 2024 Earnings CallMon, Nov 18, 2024 · 4:30 PM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q2 2024 Earnings CallWed, Aug 14, 2024 · 4:30 PM ETReplay
All 22 calls
CallWhenStatus
NRX Pharmaceuticals (NASDAQ:NRXP) Q1 2024 Earnings CallTue, May 14, 2024 · 4:30 PM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q4 2023 Earnings CallMon, Apr 01, 2024 · 8:30 AM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q3 2023 Earnings CallTue, Nov 14, 2023 · 4:30 PM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q2 2023 Earnings CallMon, Aug 14, 2023 · 4:30 PM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q1 2023 Earnings CallTue, May 16, 2023 · 4:30 PM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q4 2022 Earnings CallThu, Mar 30, 2023 · 4:30 PM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q3 2022 Earnings CallMon, Nov 14, 2022 · 8:00 AM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q2 2022 Earnings CallMon, Aug 15, 2022 · 8:30 AM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q1 2022 Earnings CallMon, May 16, 2022 · 8:30 AM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q4 2021 Earnings CallSun, Mar 20, 2022 · 8:30 PM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q3 2021 Earnings CallTue, Nov 16, 2021 · 8:30 AM ETReplay
NRX Pharmaceuticals (NASDAQ:NRXP) Q2 2021 Earnings CallTue, Aug 17, 2021 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 16, 2026 · After close+13.9%
Q2 2026Aug 14, 2026 · After close+4.9%
Q1 2026May 15, 2026 · After close−5.0%
Q4 2025Mar 24, 2026+36.2%
Q3 2025Nov 14, 2025 · After close−15.3%
Q2 2025Aug 18, 2025 · Before open−4.5%
Q1 2025May 15, 2025+7.9%
Q4 2024Mar 14, 2025 · After close−12.8%
Q3 2024Nov 14, 2024 · After close+2.6%
Q2 2024Aug 14, 2024 · After close−6.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · After close+1.6%
Q4 2023Mar 29, 2024 · After close+11.2%
Q3 2023Nov 13, 2023 · After close+4.2%
Q2 2023Aug 14, 2023 · After close+2.7%
Q1 2023May 15, 2023 · After close−7.3%
Q4 2022Mar 30, 2023 · After close−10.6%
Q3 2022Nov 14, 2022 · After close+3.6%
Q2 2022Aug 15, 2022 · After close+4.5%
Q1 2022May 16, 2022 · After close0.0%
Q4 2021Mar 31, 2022 · After close−1.2%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck20 slidesSep 14, 2026
Investor Presentation (June 2026)Investor deck21 slidesJune 2026
Investor Presentation (October 2025)Investor deck25 slidesOctober 2025
Investor Presentation (December 2024)Investor deck32 slidesDecember 2024
Investor Presentation (July 2024)Investor deck51 slidesJuly 2024
Investor Presentation (June 2023)Investor deck34 slidesJune 2023
Investor Presentation (September 2022)Investor deck29 slidesSeptember 2022
Investor Presentation (April 2022)Investor deck27 slidesApril 2022
Investor Presentation (January 2022)Investor deck45 slidesJanuary 2022
NeuroRx — SPAC Merger (December 2020)SPAC merger25 slidesDec 17, 2020

Open Decks

Financings

RaiseDate
Strategic investment of restricted common stock
Closed: US$6.5M raised
Buyers: B Group Capital (Led a consortium of biotechnology investors purchasing approximately 3.9 million shares for $6.5 million)
Use of proceeds: Capital to reach expected regulatory inflection points
Aug 18, 2025
Debt financing
Update: US$7.8M
Buyers: Universal Capital, LLC ($7.8 million in debt financing)
Use of proceeds: HOPE Therapeutics clinic acquisitions, starting with Dura Medical, Kadima and NeuroSpa clinics
May 28, 2025
Strategic investment of series A Convertible Preferred Stock of HOPE Therapeutics
Announced: US$2.5M
Use of proceeds: Support the launch of HOPE's clinic network and the closing of its announced clinic acquisitions
Apr 3, 2025
Strategic investment of nRx common stock
Cancelled: US$2M · US$2.75 a share · Warrants at US$3 for 24 months
Buyers: Smith & Sauer ($2 million in NRx common stock at $2.75 per share); Smith and Sauer ($2.0 million in NRx common stock)
Use of proceeds: To advance the new drug applications for NRX-100 and NRX-101
Mar 17, 2025
Strategic investment of series A Preferred Stock of HOPE Therapeutics
Update: US$25M
Buyers: Smith & Sauer, LLC ($25 million equity purchases in HOPE Therapeutics Series A Preferred Stock); Smith and Sauer ($25 million in newly issued Series A Preferred Stock of HOPE)
Use of proceeds: To fund planned acquisitions of HOPE interventional psychiatry clinics in a nationwide rollup
Jan 28, 2025
Registered direct offering of common stock with common stock purchase warrants
Announced: US$3.5M · US$2.88 a share · Warrants at US$2.88
Buyers: Anson Funds
Use of proceeds: New Drug Application filings for NRX-100 and NRX-101, launch of HOPE Therapeutics, and potential new pipeline products
Jan 28, 2025
Senior secured convertible promissory notes
Announced: US$5.4M · Warrants at US$3.78
Buyers: Anson Funds
Use of proceeds: New Drug Application filings for NRX-100 and NRX-101, launch of HOPE Therapeutics, and potential new pipeline products
Jan 28, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Big Rock Partners Acquisition Corp., a blank check company (SPAC). Priced at US$10.00 a unit on Nov 20, 2017.

Price
US$10.00 a unit
Units offered
6,000,000 units
Offering size
US$60 million
Underwriters' option
Up to 900,000 more units
Listing
BRPAU on the Nasdaq Capital Market
Underwriters
EarlyBirdCapital, Inc., I-Bankers Securities, Inc. · In the order on the cover
Units delivered
On or about Nov 22, 2017

Steps

StepWhen
Filed publiclyOct 13, 2017
Amended 3 timesNewest Nov 20, 2017
Shares registered with an exchangeNov 20, 2017
Declared effective by the SECNov 20, 2017
Final prospectus, with the priceNov 21, 2017

Open IPO · From the cover of the final prospectus (424B4) filed Nov 21, 2017

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2018FY2017
Revenue1.23M00000
Cost of revenue505.0K05.00K4.00K2.00K2.00K1.01M
Gross profit720.0K-5.00K-5.00K-4.00K-2.00K-2.00K-1.01M
Research and development3.78M6.20M13.4M17.0M20.3M10.6M3.50K
Selling, general and administrative13.1M13.5M14.2M27.4M74.9M11.4M2.77K1.01M134.5K
Operating income-16.2M-18.5M-27.8M-44.3M-115.8M-51.4M-713.2K-1.01M-1.19K-134.5K
Depreciation and amortization70.0K5.00K5.00K4.00K2.00K2.00K11.09M52.5K
EBITDA-16.2M-18.5M-27.8M-44.3M-115.8M-51.4M-713.2K82.4K-82.0K
Interest expense671.0K230.0K120.0K4.58M18.0K56.0K000
Income before tax-28.6M-25.1M-30.1M-39.8M-93.1M-51.8M492.6K82.4K-1.19K-105.0K
Income tax000-4.58M-21.3M17.8K84.2K16.3K0
Net income-28.6M-25.1M-30.1M-39.8M-93.1M-51.8M408.4K66.1K-1.19K-105.0K
Earnings per share, basic-1.34-2.36-3.98-0.60-1.98-1.51-0.11-0.290.00-0.12
Earnings per share, diluted-0.60-1.98-1.51-0.11-0.290.00

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2018FY2017
Cash and equivalents7.80M1.44M4.59M20.1M27.6M1.86M877.4K11.1K77.1K449.4K
Short-term investments5.97M32.0M70.8M69.0M
Receivables161.0K06.00K7.00K0831.4K
Inventory-6.00K-7.00K214.0K
Current assets8.89M3.30M6.88M25.8M32.7M2.93M69.5K30.2K123.8K536.4K
Property, plant and equipment63.0K10.0K
Goodwill1.79M0
Total assets13.0M3.65M7.32M25.8M32.7M2.94M32.1M70.8M69.9M69.6M
Accounts payable4.27M4.13M4.63M2.08M3.69M3.15M622.4K551.1K85.7K
Current liabilities28.6M21.9M19.0M15.6M11.9M46.2M622.4K567.4K375.6K93.2K
Long-term debt5.01M2.82M2.67M1.95M690.0K
Total debt631.0K6.58M9.16M10.5M518.0K797.0K1.95M690.0K
Total liabilities28.9M26.9M19.0M18.4M11.9M46.7M2.57M1.26M93.2K
Shareholders' equity-15.9M-23.2M-11.7M7.41M20.8M-43.8M-4.84M5.00M5.00M69.5M
Shares outstanding31.7M14.6M8.39M66.4M58.8M43.0M2.84M2.73M2.64M903.5K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2018FY2017
Cash from operations-14.1M-10.6M-21.7M-39.8M-37.7M-2.27M-792.7K-473.2K-30-135.8K
Capital spending00-3.00K-10.0K-7.00K-2.00K-100
Free cash flow-14.1M-10.6M-21.7M-39.8M-37.7M-2.27M-792.7K-473.2K-135.8K
Cash from investing-2.81M0-3.00K-10.0K-7.00K-2.00K40.2M-647.4K0-69.0M
Cash from financing23.3M7.49M6.20M32.2M63.5M3.25M-39.5M682.5K82.5K69.6M
Share buybacks-26.3M-40.7M70.0M
Change in cash6.35M-3.15M-15.5M-7.55M25.7M982.0K-11.1K-438.3K82.5K449.4K

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
DEFA14A · Additional proxy materialNov 5, 2026Meeting noticeSEC
DEF 14A · Proxy statementNov 5, 2026Meeting noticeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
8-K · Current reportNov 2, 2026Current reportSEC
8-K · Current reportOct 16, 2026Current reportSEC
8-K · Current reportOct 5, 2026Material contractSEC
8-K · Current reportSep 15, 2026Current reportSEC
8-K · Current reportSep 14, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportAug 17, 2026ResultsSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 7, 2026Current reportSEC
8-K · Current reportJul 22, 2026Current reportSEC
8-K · Current reportJun 4, 2026Material contractSEC
424B5 · ProspectusJun 3, 2026Offer documentSEC
8-K · Current reportJun 2, 2026Current reportSEC
424B5 · ProspectusJun 2, 2026Offer documentSEC
25-NSEMay 22, 2026Other filingsSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
8-K · Current reportMar 24, 2026Management or board changeSEC
10-K · Annual reportMar 23, 2026Annual reportSEC
DEFA14A · Additional proxy materialFeb 24, 2026Meeting noticeSEC
ARS · Annual report to shareholdersFeb 23, 2026Annual reportSEC
DEF 14A · Proxy statementFeb 23, 2026Meeting noticeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 17, 2026Insider tradeSEC
8-K · Current reportFeb 17, 2026Current reportSEC
8-K · Current reportFeb 17, 2026Current reportSEC
424B5 · ProspectusFeb 17, 2026Offer documentSEC
PRE 14A · Preliminary proxy statementFeb 13, 2026Meeting noticeSEC
8-K · Current reportFeb 2, 2026Management or board changeSEC
8-K · Current reportJan 16, 2026Current reportSEC
8-K · Current reportDec 29, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveDec 23, 2025Other filingsSEC
424B3 · ProspectusDec 22, 2025Offer documentSEC
CORRESP · Letter to the SECDec 18, 2025Other filingsSEC
S-3/A · Registration statement, amendedDec 12, 2025Offer documentSEC
8-K · Current reportNov 26, 2025Current reportSEC
8-K/A · Current report, amendedNov 21, 2025Current reportSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportOct 23, 2025Current reportSEC
8-K · Current reportSep 26, 2025Current reportSEC
8-K · Current reportSep 12, 2025Acquisition or disposalSEC
4 · Change in ownershipSep 10, 2025Insider tradeSEC
4 · Change in ownershipSep 10, 2025Insider tradeSEC
4 · Change in ownershipSep 10, 2025Insider tradeSEC
4 · Change in ownershipSep 10, 2025Insider tradeSEC
8-K · Current reportSep 8, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 21, 2025Big-stake noticeSEC
3 · Initial statement of ownershipAug 21, 2025Insider tradeSEC
8-K · Current reportAug 18, 2025ResultsSEC
424B5 · ProspectusAug 18, 2025Offer documentSEC
10-Q · Quarterly reportAug 18, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
8-K · Current reportAug 14, 2025Current reportSEC
NT 10-Q · Late filing noticeAug 14, 2025Explanation requestSEC
RW · Request to withdraw a registrationJun 24, 2025Other filingsSEC
UPLOAD · Letter from the SECJun 24, 2025Other filingsSEC
S-3 · Registration statementJun 20, 2025Offer documentSEC
8-K · Current reportJun 9, 2025Current reportSEC
8-K · Current reportMay 21, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025Current reportSEC
10-K/A · Annual report, amendedApr 30, 2025Annual reportSEC
8-K · Current reportApr 17, 2025Current reportSEC
424B3 · ProspectusApr 17, 2025Offer documentSEC
8-K · Current reportMar 21, 2025ResultsSEC
10-K · Annual reportMar 14, 2025Annual reportSEC
DMar 7, 2025Other filingsSEC
424B3 · ProspectusFeb 20, 2025Offer documentSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
8-K · Current reportFeb 3, 2025Material contractSEC
8-K · Current reportJan 29, 2025Material contractSEC
424B3 · ProspectusJan 29, 2025Offer documentSEC
8-K · Current reportJan 22, 2025Management or board changeSEC
8-K · Current reportJan 14, 2025Management or board changeSEC
8-K · Current reportJan 10, 2025Material contractSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 22, 2024Insider tradeSEC
8-K · Current reportNov 20, 2024Material contractSEC
8-K · Current reportNov 15, 2024ResultsSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
S-1 · Registration statementNov 14, 2024Offer documentSEC
8-K · Current reportOct 31, 2024Current reportSEC
8-K · Current reportOct 15, 2024Material contractSEC
8-K · Current reportOct 11, 2024Management or board changeSEC
DEF 14A · Proxy statementSep 5, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementAug 26, 2024Meeting noticeSEC
8-K · Current reportAug 20, 2024Management or board changeSEC
424B3 · ProspectusAug 14, 2024Offer documentSEC
8-K · Current reportAug 14, 2024ResultsSEC
8-K · Current reportAug 14, 2024Material contractSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
424B3 · ProspectusAug 14, 2024Offer documentSEC
8-K · Current reportAug 12, 2024Current reportSEC
424B3 · ProspectusJul 3, 2024Offer documentSEC
8-K · Current reportJun 27, 2024Current reportSEC
3 · Initial statement of ownershipJun 26, 2024Insider tradeSEC
8-K · Current reportJun 20, 2024Management or board changeSEC
8-K · Current reportMay 23, 2024Current reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportApr 30, 2024Current reportSEC
10-K/A · Annual report, amendedApr 29, 2024Annual reportSEC
8-K · Current reportApr 19, 2024Material contractSEC
424B5 · ProspectusApr 19, 2024Offer documentSEC
424B5 · ProspectusApr 18, 2024Offer documentSEC
8-K · Current reportApr 15, 2024Current reportSEC
424B3 · ProspectusApr 15, 2024Offer documentSEC
424B3 · ProspectusApr 15, 2024Offer documentSEC
8-K · Current reportApr 2, 2024ResultsSEC
10-K · Annual reportMar 29, 2024Annual reportSEC
8-K · Current reportMar 28, 2024Current reportSEC
8-K · Current reportMar 21, 2024Meeting outcomeSEC
DEFA14A · Additional proxy materialMar 20, 2024Meeting noticeSEC
DEFA14A · Additional proxy materialMar 18, 2024Meeting noticeSEC
DEFA14A · Additional proxy materialMar 13, 2024Meeting noticeSEC
DEF 14A · Proxy statementMar 11, 2024Meeting noticeSEC
8-K · Current reportMar 6, 2024Current reportSEC
8-K · Current reportFeb 28, 2024Material contractSEC
424B5 · ProspectusFeb 28, 2024Offer documentSEC
424B5 · ProspectusFeb 26, 2024Offer documentSEC
8-K · Current reportFeb 14, 2024Material contractSEC
8-K · Current reportFeb 14, 2024Material contractSEC
8-K · Current reportFeb 2, 2024Current reportSEC
8-K · Current reportJan 23, 2024Current reportSEC
3 · Initial statement of ownershipJan 16, 2024Insider tradeSEC
PRE 14A · Preliminary proxy statementDec 29, 2023Meeting noticeSEC
8-K · Current reportDec 29, 2023Management or board changeSEC
8-K · Current reportDec 21, 2023Current reportSEC
ARS · Annual report to shareholdersNov 22, 2023Annual reportSEC
DEF 14A · Proxy statementNov 22, 2023Meeting noticeSEC
8-K/A · Current report, amendedNov 22, 2023Current reportSEC
8-K · Current reportNov 21, 2023Current reportSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
8-K · Current reportOct 23, 2023Current reportSEC
3 · Initial statement of ownershipSep 19, 2023Insider tradeSEC
8-K · Current reportSep 14, 2023Management or board changeSEC
4 · Change in ownershipSep 11, 2023Insider tradeSEC
4 · Change in ownershipSep 11, 2023Insider tradeSEC
8-K · Current reportSep 1, 2023Material contractSEC
8-K · Current reportAug 31, 2023Current reportSEC
424B3 · ProspectusAug 31, 2023Offer documentSEC
4 · Change in ownershipAug 24, 2023Insider tradeSEC
4 · Change in ownershipAug 23, 2023Insider tradeSEC
8-K · Current reportAug 14, 2023Material contractSEC
424B5 · ProspectusAug 14, 2023Offer documentSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportJul 28, 2023Material contractSEC
424B5 · ProspectusJun 8, 2023Offer documentSEC
8-K/A · Current report, amendedJun 7, 2023Material contractSEC
8-K · Current reportJun 6, 2023Material contractSEC
8-K · Current reportJun 5, 2023Material contractSEC
10-K/A · Annual report, amendedMay 26, 2023Annual reportSEC
10-Q · Quarterly reportMay 15, 2023Quarterly reportSEC
10-K/A · Annual report, amendedMay 1, 2023Annual reportSEC
8-K · Current reportApr 21, 2023Current reportSEC
10-K · Annual reportMar 31, 2023Annual reportSEC
8-K · Current reportMar 31, 2023ResultsSEC
424B5 · ProspectusMar 14, 2023Offer documentSEC
8-K/A · Current report, amendedMar 14, 2023Material contractSEC
8-K · Current reportMar 13, 2023Current reportSEC
424B5 · ProspectusMar 10, 2023Offer documentSEC
8-K · Current reportMar 9, 2023Material contractSEC
8-K · Current reportMar 3, 2023Meeting outcomeSEC
8-K · Current reportFeb 24, 2023Meeting outcomeSEC
8-K · Current reportFeb 23, 2023Management or board changeSEC
5 · Annual statement of ownershipFeb 14, 2023Insider tradeSEC
8-K · Current reportFeb 13, 2023Current reportSEC
8-K · Current reportFeb 2, 2023Meeting outcomeSEC
DEF 14A · Proxy statementJan 10, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementDec 23, 2022Meeting noticeSEC
4 · Change in ownershipDec 19, 2022Insider tradeSEC
4 · Change in ownershipDec 19, 2022Insider tradeSEC
4/A · Change in ownership, amendedDec 19, 2022Insider tradeSEC
4 · Change in ownershipDec 9, 2022Insider tradeSEC
424B5 · ProspectusDec 2, 2022Offer documentSEC
4 · Change in ownershipDec 1, 2022Insider tradeSEC
4 · Change in ownershipNov 29, 2022Insider tradeSEC
4 · Change in ownershipNov 28, 2022Insider tradeSEC
4/A · Change in ownership, amendedNov 23, 2022Insider tradeSEC
4 · Change in ownershipNov 22, 2022Insider tradeSEC
4 · Change in ownershipNov 22, 2022Insider tradeSEC
4 · Change in ownershipNov 22, 2022Insider tradeSEC
4 · Change in ownershipNov 21, 2022Insider tradeSEC
4 · Change in ownershipNov 18, 2022Insider tradeSEC
4 · Change in ownershipNov 15, 2022Insider tradeSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
8-K · Current reportNov 14, 2022ResultsSEC
8-K · Current reportNov 9, 2022Material contractSEC
SC 13D · Big-stake noticeSep 13, 2022Big-stake noticeSEC
8-K · Current reportAug 22, 2022Current reportSEC
10-Q · Quarterly reportAug 15, 2022Quarterly reportSEC
10-Q/A · Quarterly report, amendedAug 12, 2022Quarterly reportSEC
10-Q/A · Quarterly report, amendedAug 12, 2022Quarterly reportSEC
8-K · Current reportAug 12, 2022Current reportSEC

This page holds 200 of 480 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from NRX Pharmaceuticals, Inc.’s releases · as of Nov 16, 2026

Common shares
44,327,982
Fully diluted
44,327,982

Fully diluted

LineSharesAs of
Common shares44,327,982Nov 16, 2026

Share count over time

CountShares
Nov 16, 202644,327,982

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
B Group, Inc.4.28M9.6%US$12.5MSep 30, 2026
Vanguard2.07M4.7%US$6.03MSep 30, 2026
Ameriprise1.42M3.2%US$4.13MSep 30, 2026
Balyasny Asset Management L.P.1.05M2.4%US$3.08MSep 30, 2026
Marshall Wace, LLP995K2.2%US$2.91MSep 30, 2026
AdvisorShares Investments LLC805K1.8%US$2.35MSep 30, 2026
Citadel747K1.7%US$2.18MSep 30, 2026
Commonwealth Equity Services, LLC591K1.3%US$1.73MSep 30, 2026
Geode Capital446K1.0%US$1.3MSep 30, 2026
UBS379K0.86%US$1.11MSep 30, 2026
All 47 holders
HolderSharesOf the companyValueAs of
BlackRock223K0.50%US$651KSep 30, 2026
State Street125K0.28%US$366KSep 30, 2026
Prime Capital Investment Advisors, LLC125K0.28%US$364KSep 30, 2026
Bleakley Financial Group, LLC117K0.26%US$342KSep 30, 2026
Morgan Stanley102K0.23%US$298KSep 30, 2026
Northern Trust95,0640.21%US$278KSep 30, 2026
Man Group plc86,8180.20%US$254KSep 30, 2026
Chicago Partners Investment Group LLC47,5420.11%US$118KSep 30, 2026
One Wealth Management Investment & Advisory Services, LLC45,8410.10%US$134KSep 30, 2026
Millennium42,0610.09%US$123KSep 30, 2026
Two Sigma41,9380.09%US$122KSep 30, 2026
Qube Research & Technologies Ltd39,2040.09%US$114KSep 30, 2026
Jane Street36,2930.08%US$106KSep 30, 2026
Global Retirement Partners, LLC30,4000.07%US$88,768Sep 30, 2026
Group One Trading LLC30,1430.07%US$88,018Sep 30, 2026
Engineers Gate Manager LP22,9410.05%US$66,988Sep 30, 2026
SBI Securities Co., Ltd.20,0010.05%US$58,403Sep 30, 2026
Truist Financial Corp20,0000.05%US$58,400Sep 30, 2026
Ethos Financial Group, LLC15,9000.04%US$46,428Sep 30, 2026
Cresset Asset Management, LLC15,0000.03%US$43,800Sep 30, 2026
Sjbenen Advisory, LLC15,0000.03%US$41,978Sep 30, 2026
Schonfeld Strategic Advisors LLC14,8010.03%US$43,218Sep 30, 2026
Tower Research Capital LLC (TRC)14,2730.03%US$41,677Sep 30, 2026
Hudson Bay Capital Management LP12,4300.03%US$36,296Sep 30, 2026
Renaissance Technologies12,3000.03%US$35,916Sep 30, 2026
Susquehanna12,1970.03%US$35,615Sep 30, 2026
Persistent Asset Partners Ltd10,0630.02%US$29,384Sep 30, 2026
Security National Bank4,200<0.01%US$12,264Sep 30, 2026
Wells Fargo4,000<0.01%US$11,680Sep 30, 2026
JPMorgan3,803<0.01%US$11,104Sep 30, 2026
RBC3,121<0.01%US$9,000Sep 30, 2026
Smartleaf Asset Management LLC2,500<0.01%US$7,300Sep 30, 2026
Barclays1,550<0.01%US$4,526Sep 30, 2026
Evelyn Partners Group Ltd941<0.01%US$2,748Sep 30, 2026
Osaic Holdings, Inc.600<0.01%US$1,752Sep 30, 2026
Larson Financial Group LLC22<0.01%US$64Sep 30, 2026
Steward Partners Investment Advisory, LLC1<0.01%US$3Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.27M2.9%US$5.18MJun 30, 2026
AdvisorShares Psychedelics ETF659K1.5%US$2.7MJun 30, 2026
Vanguard Extended Market Index Fund291K0.66%US$1.19MJun 30, 2026
Fidelity Extended Market Index Fund131K0.30%US$580KMay 31, 2026
iShares Micro-Cap ETF105K0.24%US$429KJun 30, 2026
Fidelity Series Total Market Index Fund48,1230.11%US$213KMay 31, 2026
Fidelity Total Market Index Fund30,8120.07%US$136KMay 31, 2026
Fidelity Nasdaq Composite Index Fund21,9760.05%US$97,134May 31, 2026
Vanguard Balanced Index Fund21,7170.05%US$88,823Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund15,4590.03%US$63,227Jun 30, 2026
All 13 holders
HolderSharesOf the companyValueAs of
1290 VT Micro Cap Portfolio7,1130.02%US$29,092Jun 30, 2026
Victory Extended Market Index Fund4,275<0.01%US$13,466Jul 31, 2026
Total Stock Market Index Trust634<0.01%US$2,593Jun 30, 2026

Big stakes

StakeStakeSharesDateFiling
B Group, Inc.12.62%3MAug 18, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Lori Wittman
Other companies: AH Realty Trust, Inc. (Director · Since at least Jun 17, 2026); NetSTREIT Corp. (Director · Since at least Aug 12, 2020); Chiron Real Estate Inc. (Director · Since at least May 30, 2018); Care Capital Properties Inc (EVP and CFO · Jul 31, 2015 – Aug 17, 2017 · Past)
CFO, Director · Nov 20, 2017 – Nov 20, 2017 · Past
Michael Abrams
Other companies: Arch Therapeutics Inc (CHIEF FINANCIAL OFFICER · May 10, 2021 – Aug 31, 2023 · Past); Silvergraph International Inc (Director · Dec 30, 2011 – Dec 30, 2011 · Past); FitLife Brands, Inc. (CHIEF FINANCIAL OFFICER, Director · Aug 20, 2009 – Dec 31, 2016 · Past)
Chief Financial Officer · Since at least Nov 18, 2024
Seth Van Voorhees
Other companies: PDS Biotechnology Corporation (Chief Financial Officer · Jan 1, 2021 – Jun 15, 2021 · Past); Research Frontiers Incorporated (CFO & VP-Business Development · Dec 31, 2017 – Feb 21, 2020 · Past)
CHIEF FINANCIAL OFFICER · Jun 13, 2022 – Dec 16, 2022 · Past
Stephen H. Willard
Other companies: Longeveron Inc. (Chief Executive Officer · Since at least Feb 11, 2026); E*TRADE Financial LLC (Director · May 10, 2012 – May 9, 2013 · Past)
CHIEF EXECUTIVE OFFICER, Director · Jul 12, 2022 – Dec 16, 2022 · Past
Chaim Hurvitz
Other companies: Dror Ortho-Design Inc. (Chairman of The Board · Since at least Jun 17, 2024)
Director · Since at least Apr 9, 2025
Herbert Raymond McMaster
Other companies: Zoom Communications, Inc. (Director · Since at least May 6, 2020)
Director · May 26, 2021 – Aug 26, 2021 · Past
Ira S Strassberg
Other companies: Continental Building Products Inc (Director · Mar 10, 2017 – Feb 3, 2020 · Past)
Chief Financial Officer · Mar 15, 2022 – Mar 15, 2022 · Past
Richard Clavano Narido
Other companies: Lucira Health Inc (Chief Financial Officer · Nov 15, 2022 – Mar 3, 2023 · Past)
Interim CFO · Sep 13, 2023 – Sep 13, 2023 · Past
William Fricker
Other companies: Immunomedics Inc (Principal Accounting Officer · Aug 23, 2018 – Oct 23, 2020 · Past)
CFO & Treasurer · May 24, 2021 – May 24, 2021 · Past
Aaron GorovitzDirector · May 24, 2021 – Aug 30, 2023 · Past
All 28 people
PersonSeat
Albert G RexDirector · Nov 20, 2017 – Nov 20, 2017 · Past
Alessandra DaigneaultGeneral Counsel & Secretary · May 24, 2021 – Aug 19, 2021 · Past
Brian KorbManaging Partner, astr partners · Since at least Oct 30, 2026
Daniel TroyDirector · May 24, 2021 – May 24, 2021 · Past
Dennis K. McBrideChief Strategy Officer · Since at least Jun 13, 2024
Glenn D. TysonChief Commercial Officer · Since Apr 13, 2026
Hope TherapeuticsInc.Chief Business Officer · Since at least Dec 1, 2025
Janet RehnquistDirector · Dec 28, 2023 – Dec 28, 2023 · Past
Jonathan C. JavittFounder, Chairman & Chief Scientist; Co-CEO HOPE Therapeutics · Since at least May 24, 2021
Joseph Michael CasperChief Operating Officer · Since at least Jan 27, 2026
Joshua BrownChief Medical Innovation Officer · Since at least Mar 2, 2026
Patrick FlynnChief Operating Officer · Since at least May 24, 2021
Richard AckermanPresident & CEO, Director · May 24, 2021 – May 24, 2021 · Past
Richard BirdoffDirector · Nov 20, 2017 – Nov 20, 2017 · Past
Rick PanicucciChief Technology Officer · Since at least Nov 4, 2026
Robert BesthofInterim CEO · May 24, 2021 – Mar 8, 2022 · Past
Sharon GliedDirector · May 24, 2021 – Oct 21, 2022 · Past
Troy T TaylorDirector · Nov 20, 2017 – Nov 20, 2017 · Past

Open People

Log in to ask 6ix AI your own questions about NRX Pharmaceuticals, Inc.